Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Moore

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Breast Cancer Research and Treatment|June 15, 2013
Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for interventionChris I Flowers, Cristina O'Donoghue, Dan Moore, et al.
American Journal of Obstetrics and Gynecology|April 29, 2006
Is there a useful cesarean birth measure? Assessment of the nulliparous term singleton vertex cesarean birth rate as a tool for obstetric quality improvementElliott K Main, Dan Moore, Bill Farrell, et al.
Cancer Cell|November 13, 2007
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumorsMona L Gauthier, Hal K Berman, Caroline Miller, et al.
Breast Cancer Research and Treatment|July 17, 2012
The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivorsMeredith Bock, Dan Moore, Jimmy Hwang, et al.
Journal of the National Cancer Institute|February 7, 2013
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?Dejana Braithwaite, Weiwei Zhu, Rebecca A Hubbard, et al.
Breast Cancer Research : BCR|November 1, 2013
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic riskChristina Yau, John Sninsky, Shirley Kwok, et al.
Journal of the National Cancer Institute|November 21, 2002
Arsenic-related chromosomal alterations in bladder cancerLee E Moore, Allan H Smith, Clarence Eng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted deliveryJohn W Park, Keelung Hong, Dmitri B Kirpotin, et al.
Breast Cancer Research and Treatment|July 29, 2011
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)Cheryl Lin, Meredith Becker Buxton, Dan Moore, et al.
Muscle & Nerve|March 7, 2018
Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trialBjörn Oskarsson, Dan Moore, Tahseen Mozaffar, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|June 15, 2013
Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for interventionChris I Flowers, Cristina O'Donoghue, Dan Moore, et al.
American Journal of Obstetrics and Gynecology|April 29, 2006
Is there a useful cesarean birth measure? Assessment of the nulliparous term singleton vertex cesarean birth rate as a tool for obstetric quality improvementElliott K Main, Dan Moore, Bill Farrell, et al.
Cancer Cell|November 13, 2007
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumorsMona L Gauthier, Hal K Berman, Caroline Miller, et al.
Breast Cancer Research and Treatment|July 17, 2012
The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivorsMeredith Bock, Dan Moore, Jimmy Hwang, et al.
Journal of the National Cancer Institute|February 7, 2013
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?Dejana Braithwaite, Weiwei Zhu, Rebecca A Hubbard, et al.
Breast Cancer Research : BCR|November 1, 2013
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic riskChristina Yau, John Sninsky, Shirley Kwok, et al.
Journal of the National Cancer Institute|November 21, 2002
Arsenic-related chromosomal alterations in bladder cancerLee E Moore, Allan H Smith, Clarence Eng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted deliveryJohn W Park, Keelung Hong, Dmitri B Kirpotin, et al.
Breast Cancer Research and Treatment|July 29, 2011
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)Cheryl Lin, Meredith Becker Buxton, Dan Moore, et al.
Muscle & Nerve|March 7, 2018
Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trialBjörn Oskarsson, Dan Moore, Tahseen Mozaffar, et al.
Pageof 6